May 11, 2010
COTI‐2 Receives Favourable Independent Pre‐Investigational New Drug Gap Analysis Report
Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) announced today that it received a favourable Pre‐Investigational New Drug (pre‐IND) gap analysis report... Read More
Apr 22, 2010
Asuragen Sets Sights on Pancreatic Cancer Screen Through TGen Collaboration
genomeweb - Asuragen this week announced that it has signed a deal to work with TGen to develop a test to detect pancreatic cancer using blood-based microRNAs as biomarkers... Read More
Apr 12, 2010
TD2 partners with Horizon Discovery to offer an integrated personalized medicine service
A strategic alliance announced today between TGen Drug Development (TD2) and Horizon Discovery Limited will significantly advance personalized medicine... Read More
Apr 6, 2010
TGen Drug Development accompanies GPEC to BayBio2010
Scottsdale-based TD2 will join the Greater Phoenix Economic Council (GPEC) this week at BayBio2010... ... Read More
Mar 23, 2010
TGen Drug Development accompanies GPEC to BayBio2010
Scottsdale-based TD2 will join the Greater Phoenix Economic Council (GPEC) this week at BayBio2010... ...
Read More
Mar 11, 2010
Effort aims to spike breast cancer with new approach
TGen, Virginia G. Piper Cancer Center and Side-Out Foundation team up for ‘next generation’ treatment
Many women live with breast cancer that does not respond to standard medical treatment, a condition that researchers at the Virginia G. Piper Cancer Center at Scottsdale Healthcare want to change by aggressively targeting specific genes... Read More
Feb. 19, 2010
Rondaxe and TD2 form strategic drug development alliance
TGen Drug Development (TD2) gets skills in drug manufacturing and quality control,
Rondaxe receives access to TD2’s expertise in clinical trials and regulatory navigation
TD2 and Rondaxe Enterprises have announced a strategic alliance that will help
emerging companies speed new high-quality treatments to cancer patients.... Read More
Jan. 21, 2010
New study shows TGen spin-off boosts Scottsdale economy
TGen Drug Development (TD2) creates jobs, revenues, related businesses; Total
economic impact on the city in 2015 is projected to top $239 million
TD2 is poised to play a significant role in the expansion of Scottsdale's
biomedical industry, fostering new jobs and city revenues, and prompting the
creation of more related businesses... Read More
Jan. 12, 2010
TD2 and Critical Outcome Technologies Inc. develop novel anti-cancer drug
World renowned clinical oncologist and TGen Drug Development chosen to lead drug development program for COTI-2
TD2 and Critical Outcome Technologies Inc. announced today that they will work
together to obtain approval of clinical trials for a promising new anti-cancer drug called
COTI-2... Read More
Nov. 18, 2009
TGen Drug Development (TD2) establishes European footprint
Alliance with France's Institut Paoli-Calmettes focuses on cancer
TD2 and the Institut Paoli-Calmettes (IPC) have forged a strategic alliance that
will enable both to maximize their worldwide contributions in the treatment of
cancer patients... Read More
Aug. 5, 2008
Apthera and TGen Drug Development Services (TD2) Sign Master Services Agreement
TD2 to Provide Strategic Drug Development Services
Apthera, Inc., a Scottsdale, Arizona-based biotechnology company focused on cancer
immunotherapy, today announced an alliance with TD2... Read More